This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

Welcome to Novo Nordisk Rare Diseases Science Hub

 

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a non-US healthcare professional.

Pratima
Chowdary
Royal Free Hospital, London, United Kingdom

Pratima Chowdary is Professor of Haemophilia and Haemostasis, Dept. of Haematology, University College of London (UCL) and Centre Director for the Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital and. In addition, she serves as co-director for the National Haemophilia Database, run by United Kingdom Haemophilia Centre Doctors Organisation (UKHCDO).

 

Her clinical interests include the care of patients with Haemophilia and related bleeding disorders. Her primary research interests include personalised management of Haemophilia, novel therapies in haemophilia, including gene therapy, outcome assessments, haemophilic arthropathy and acquired coagulopathy. She is active in clinical trials and is the chief investigator for several non-interventional and interventional studies, including  UCL sponsored gene therapy studies.

 

She has authored several peer-reviewed publications and is a chair and member of various national and international working parties,  data safety monitoring boards, trial steering committees. She is a member of numerous professional societies, including the International Society on Thrombosis and Haemostasis, British Society of Haemostasis and Thrombosis, European Association of Allied Bleeding disorders and the World Federation of Haemophilia.

Christoph Königs

University Hospital Frankfurt, Frankfurt am Main, Germany


Christoph Königs is based at the Pediatric Hemophilia Center, University Hospital Frankfurt, Germany since 2002. He has received his degree in science from Monash University, Melbourne, Australia in 1998 and his medical degree from Goethe University Frankfurt, Germany in 2002. For both, his MD and PhD thesis Christoph isolated ligands to clinically relevant structures of protein receptors and RNA. 

 

The main clinical and scientific interest of his research team is the understanding and modification of the immune response to coagulations factors. The main clinical focus has been developing and improving therapies for children and adolescents with coagulation disorders with a focus on patient education and shared decision making. 

 

Christoph has specialized in Pediatrics and Adolescent Medicine and also in Hemostasis. He is a member of several national and international scientific societies and committees. He co-chairs the “Standing Committee Hemophilia” of the Society for Thrombosis and Hemostasis (GTH), the national registry on PUPs with newly diagnosed hemophilias in Germany “GEPHARD” and the scientific advisory council of PedNet. Christoph is closely working together with the German patient organizations i.e. as a deputy chair of the medical advisory board. 


Read full bio

Gili Kenet

Tel Aviv University , Tel Aviv, Israel


Gili Kenet is a Pediatric Hematologist, Professor and former Chair of the Hematology Department at the Sackler Medical School, Tel Aviv University.

 

Professor Kenet received her Medical Degree from the Hebrew University in Jerusalem.  Her research projects have been focused on neonatal hemostasis, childhood stroke and pediatric thrombophilia, as well as the research of new therapy modes applied for people with hemophilia and severe bleeding disorders.  She was awarded national grants for pediatric hematology and cancer research, study of rFVIIa mode of action, epidemiology of inhibitor evolution in hemophilia and for personalized tailoring of bypass agent therapy, and applying global hemostasis assays. Prof. Kenet pioneered in gene therapy clinical trials in Israel and novel non replacement drugs in Hemophilia.

 

Professor Kenet is the author of over 200 peer reviewed scientific publications, review articles and book chapters.  An active member of the World Federation of Hemophilia, Israeli Society of Pediatric Hematology and Oncology, and the American Society of Hematology, an active reviewer for high impact thrombosis journals and an editorial board member of the Haemophilia journal.  Former Chairperson of the Israeli Society of Thrombosis and Hemostasis and Chairperson of the Pediatric and Peri-natal Hemostasis Scientific Subcommittee of ISTH.  Currently co-chairs the FVIII/FIX and rare bleeding disorders of the SSC of ISTH.


Read full bio